Regulation of tumor phenotypes by caveolin-1 and sphingolipid-controlled membrane signaling complexes

Biochimica et Biophysica Acta - General Subjects

Volumn 1780, Issue 3, 2008, Pages 585-596

  Prinetti, Alessandro ^a   Prioni, Simona ^a   Loberto, Nicoletta ^a   Aureli, Massimo ^a   Chigorno, Vanna ^a   Sonnino, Sandro ^a  

^a UNIVERSITY OF MILAN   (Italy)

Author keywords

Caveolin 1; Glycosynapse; GM3 ganglioside; Lipid raft; Sphingolipid; Tumor cell motility

Indexed keywords

BREFELDIN A; CAVEOLIN 1; GANGLIOSIDE GM3; LIPID; SPHINGOLIPID;

CANCER CONTROL; CAVEOLA; DRUG BINDING; HUMAN; LIPID RAFT; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH;

CAVEOLIN 1; CELL MEMBRANE; HUMANS; NEOPLASMS; PHENOTYPE; SIGNAL TRANSDUCTION; SPHINGOLIPIDS;

EID: 40749087098     PISSN: 03044165     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbagen.2007.08.002     Document Type: Review

References (149)

1. Svennerholm L. Ganglioside designation. Adv. Exp. Med. Biol. 125 (1980) 11
2. IUPAC-IUBMB, and Joint Commission on Biochemical Nomenclature. Nomenclature of glycolipids. Carbohydr. Res. 312 (1998) 167-175
3. Hakomori S.-I. Aberrant glycosylation in cancer cell membranes as focused on glycolipids: overview and perspectives. Cancer Res. 45 (1985) 2405-2414
4. Hakomori S.-I. Tumor malignancy defined by aberrant glycosylation and sphingo(glyco)lipid metabolism. Cancer Res. 56 (1996) 5309-5318
5. Miyazaki K., Ohmori K., Izawa M., Koike T., Kumamoto K., Furukawa K., Ando T., Kiso M., Yamaji T., Hashimoto Y., Suzuki A., Yoshida A., Takeuchi M., and Kannagi R. Loss of disialyl Lewis(a), the ligand for lymphocyte inhibitory receptor sialic acid-binding immunoglobulin-like lectin-7 (Siglec-7) associated with increased sialyl Lewis(a) expression on human colon cancers. Cancer Res. 64 (2004) 4498-4505
6. Kannagi R., Izawa M., Koike T., Miyazaki K., and Kimura N. Carbohydrate-mediated cell adhesion in cancer metastasis and angiogenesis. Cancer Sci. 95 (2004) 377-384
7. Carcel-Trullols J., Stanley J.S., Saha R., Shaaf S., Bendre M.S., Monzavi-Karbassi B., Suva L.J., and Kieber-Emmons T. Characterization of the glycosylation profile of the human breast cancer cell line, MDA-231, and a bone colonizing variant. Int. J. Oncol. 28 (2006) 1173-1183
8. Hakomori S. Carbohydrate-to-carbohydrate interaction, through glycosynapse, as a basis of cell recognition and membrane organization. Glycoconj. J. 21 (2004) 125-137
9. Hakomori S. Glycosynapses: microdomains controlling carbohydrate-dependent cell adhesion and signaling. An. Acad. Bras. Cienc. 76 (2004) 553-572
10. Hakomori S. Glycosylation defining cancer malignancy: new wine in an old bottle. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 10231-10233
11. Satoh M., Handa K., Saito S., Tokuyama S., Ito A., Miyao N., Orikasa S., and Hakomori S.-I. Disialosyl galactosylgloboside as an adhesion molecule expressed on renal cell carcinoma and its relationship to metastatic potential. Cancer Res. 56 (1996) 1932-1938
12. Ohyama C., Orikasa S., Kawamura S., Satoh M., Saito S., Fukushi Y., Levery S.B., and Hakomori S. Galactosylgloboside expression in seminoma. Inverse correlation with metastatic potential. Cancer 76 (1995) 1043-1050
13. Kawamura S., Ohyama C., Watanabe R., Satoh M., Saito S., Hoshi S., Gasa S., and Orikasa S. Glycolipid composition in bladder tumor: a crucial role of GM3 ganglioside in tumor invasion. Int. J. Cancer 94 (2001) 343-347
14. Watanabe R., Ohyama C., Aoki H., Takahashi T., Satoh M., Saito S., Hoshi S., Ishii A., Saito M., and Arai Y. Ganglioside GM3 overexpression induces apoptosis and reduces malignant potential in murine bladder cancer. Cancer Res. 62 (2002) 3850-3854
15. Ladisch S., Kitada S., and Hays E.F. Gangliosides shed by tumor cells enhance tumor formation in mice. J. Clin. Invest. 79 (1987) 1879-1882
16. Deng W., Li R., and Ladisch S. Influence of cellular ganglioside depletion on tumor formation. J. Natl. Cancer Inst. 92 (2000) 912-917
17. Ladisch S., Li R., and Olson E. Ceramide structure predicts tumor ganglioside immunosuppressive activity. Proc. Natl. Acad. Sci. U. S. A. 91 (1994) 1974-1978
18. Ladisch S., Fumin C., Ruixiang L., Cogen P., and Johnson D. Detection of medulloblastoma and astrocytoma-associated ganglioside GD3 in cerebrospinal fluid. Cancer Lett. 120 (1997) 71-78
19. Chang F., Li R., and Ladisch S. Shedding of gangliosides by human medulloblastoma cells. Exp. Cell Res. 234 (1997) 341-346
20. Hakomori S., Handa K., Iwabuchi K., Yamamura S., and Prinetti A. New insights in glycosphingolipid function: "glycosignaling domain," a cell surface assembly of glycosphingolipids with signal transducer molecules, involved in cell adhesion coupled with signaling. Glycobiology 8 (1998) xi-xix
21. Satoh M., Ito A., Nojiri H., Handa K., Numahata K., Ohyama C., Saito S., Hoshi S., and Hakomori S. Enhanced GM3 expression, associated with decreased invasiveness, is induced by brefeldin A in bladder cancer cells. Int. J. Oncol. 19 (2001) 723-731
22. Nojiri H., Yamana H., Shirouzu G., Suzuki T., and Isono H. Glycotherapy for cancer: remodeling of ganglioside pattern as an effective approach for cancer therapy. Cancer Detec. Prev. 26 (2002) 114-120
23. Prinetti A., Basso L., Appierto V., Villani M.G., Valsecchi M., Loberto N., Prioni S., Chigorno V., Cavadini E., Formelli F., and Sonnino S. Altered sphingolipid metabolism in N-(4-Hydroxyphenyl)-retinamide-resistant A2780 human ovarian carcinoma cells. J. Biol. Chem. 278 (2003) 5574-5583
24. Ono M., Handa K., Withers D.A., and Hakomori S.-I. Motility inhibition and apoptosis are induced by metastasis-suppressing gene product CD82 and its analogue CD9, with concurrent glycosylation. Cancer Res. 59 (1999) 2335-2339
25. Ono M., Handa K., Sonnino S., Withers D.A., Nagai H., and Hakomori S. GM3 ganglioside inhibits CD9-facilitated haptotactic cell motility: coexpression of GM3 and CD9 is essential in the downregulation of tumor cell motility and malignancy. Biochemistry 40 (2001) 6414-6421
26. Iwabuchi K., Handa K., and Hakomori S. Separation of "glycosphingolipid signaling domain" from caveolin-containing membrane fraction in mouse melanoma B16 cells and its role in cell adhesion coupled with signaling. J. Biol. Chem. 273 (1998) 33766-33773
27. Kojima N., Shiota M., Sadahira Y., Handa K., and Hakomori S. Cell adhesion in a dynamic flow system as compared to static system. Glycosphingolipid-glycosphingolipid interaction in the dynamic system predominates over lectin- or integrin-based mechanisms in adhesion of B16 melanoma cells to non-activated endothelial cells. J. Biol. Chem. 267 (1992) 17264-17270
28. Rothberg K.G., Heuser J.E., Donzell W.C., Ying Y.S., Glenney J.R., and Anderson R.G. Caveolin, a protein component of caveolae membrane coats. Cell 68 (1992) 673-682
29. Williams T.M., and Lisanti M.P. The caveolin proteins. Genome Biol. 5 (2004) 214
30. Anderson R.G. The caveolae membrane system. Ann. Rev. Biochem. 67 (1998) 199-225
31. Harder T., and Simons K. Caveolae, DIGs, and the dynamics of sphingolipid-cholesterol microdomains. Curr. Opin. Cell Biol. 9 (1997) 534-542
32. Song K.S., Li S., Okamoto T., Quilliam L.A., Sargiacomo M., and Lisanti M.P. Co-purification and direct interaction of Ras with caveolin, an integral membrane protein of caveolae microdomains. Detergent-free purification of caveolae microdomains. J. Biol. Chem. 271 (1996) 9690-9697
33. Couet J., Li S., Okamoto T., Ikezu T., and Lisanti M.P. Identification of peptide and protein ligands for the caveolin-scaffolding domain. Implications for the interaction of caveolin with caveolae-associated proteins. J. Biol. Chem. 272 (1997) 6525-6533
34. Couet J., Sargiacomo M., and Lisanti M.P. Interaction of a receptor tyrosine kinase, EGF-R, with caveolins. Caveolin binding negatively regulates tyrosine and serine/threonine kinase activities. J. Biol. Chem. 272 (1997) 30429-30438
35. Pike L.J. Growth factor receptors, lipid rafts and caveolae: an evolving story. Biochim. Biophys. Acta 1746 (2005) 260-273
36. Sargiacomo M., Scherer P.E., Tang Z., Kubler E., Song K.S., Sanders M.C., and Lisanti M.P. Oligomeric structure of caveolin: implications for caveolae membrane organization. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 9407-9411
37. Liu J., Oh P., Horner T., Rogers R.A., and Schnitzer J.E. Organized endothelial cell surface signal transduction in caveolae distinct from glycosylphosphatidylinositol-anchored protein microdomains. J. Biol. Chem. 272 (1997) 7211-7222
38. Engelman J.A., Zhang X.L., Razani B., Pestell R.G., and Lisanti M.P. p42/44 MAP kinase-dependent and -independent signaling pathways regulate caveolin-1 gene expression. Activation of Ras-MAP kinase and protein kinase A signaling cascades transcriptionally down-regulates caveolin-1 promoter activity. J. Biol. Chem. 274 (1999) 32333-32341
39. Williams T.M., Medina F., Badano I., Hazan R.B., Hutchinson J., Muller W.J., Chopra N.G., Scherer P.E., Pestell R.G., and Lisanti M.P. Caveolin-1 gene disruption promotes mammary tumorigenesis and dramatically enhances lung metastasis in vivo: role of Cav-1 in cell invasiveness and matrix metalloproteinase (MMP-2/9) secretion. J. Biol. Chem. 279 (2004) 51630-51646
40. Wiechen K., Diatchenko L., Agoulnik A., Scharff K.M., Schober H., Arlt K., Zhumabayeva B., Siebert P.D., Dietel M., Schafer R., and Sers C. Caveolin-1 is down-regulated in human ovarian carcinoma and acts as a candidate tumor suppressor gene. Am. J. Pathol. 159 (2001) 1635-1643
41. Lee S.W., Reimer C.L., Oh P., Campbell D.B., and Schnitzer J.E. Tumor cell growth inhibition by caveolin re-expression in human breast cancer cells. Oncogene 16 (1998) 1391-1397
42. Bender F.C., Reymond M.A., Bron C., and Quest A.F.G. Caveolin-1 levels are down-regulated in human colon tumors, and ectopic expression of caveolin-1 in colon carcinoma cell lines reduces cell tumorigenicity. Cancer Res. 60 (2000) 5870-5878
43. Miotti S., Tomassetti A., Facetti I., Sanna E., Berno V., and Canevari S. Simultaneous expression of caveolin-1 and E-cadherin in ovarian carcinoma cells stabilizes adherens junctions through inhibition of Src-related kinases. Am. J. Pathol. 167 (2005) 1411-1427
44. Ho C.-C., Huang P.-H., Huang H.-Y., Chen Y.-H., Yang P.-C., and Hsu S.-M. Up-regulated caveolin-1 accentuates the metastasis capability of lung adenocarcinoma by inducing filopodia formation. Am. J. Pathol. 161 (2002) 1647-1656
45. Timme T.L., Golstsov A., Tahir S., Li L., Wang J., Ren C., Johnston R.N., and Thompson T.C. Caveolin-1 is regulated by c-myc and suppresses c-myc-induced apoptosis. Oncogene 19 (2000) 3256-3265
46. Roche S., Koegl M., Barone M., Roussel M., and Courtneidge S. DNA synthesis induced by some but not all growth factors requires Src family protein tyrosine kinases. Mol. Cell. Biol. 15 (1995) 1102-1109
47. Roche S., Fumagalli S., and Courtneidge S. Requirement for Src family protein tyrosine kinases in G2 for fibroblast cell division. Science 269 (1995) 1567-1569
48. Roche S., McGlade J., Jones M., Gish G.D., Pawson T., and Courtneidge S. Requirement of phospholipase C gamma, the tyrosine phosphatase Syp and the adaptor proteins Shc and Nck for PDGF-induced DNA synthesis: evidence for the existence of Ras-dependent and Ras-independent pathways. EMBO J. 15 (1996) 4940-4948
49. Roche S., Downward J., Raynal P., and Courtneidge S.A. A function for phosphatidylinositol 3-kinase beta (p85alpha-p110beta) in fibroblasts during mitogenesis: requirement for insulin- and lysophosphatidic acid-mediated signal transduction. Mol. Cell. Biol. 18 (1998) 7119-7129
50. Manes G., Bello P., and Roche S. Slap negatively regulates Src mitogenic function but does not revert Src-induced cell morphology changes. Mol. Cell. Biol. 20 (2000) 3396-3406
51. Furstoss O., Dorey K., Simon V., Barilà D., Superti-Furga G., and Roche S. c-Abl is an effector of Src for growth factor-induced c-myc expression and DNA synthesis. EMBO J. 21 (2002) 514-524
52. Boureux A., Furstoss O., Simon V., and Roche S. Abl tyrosine kinase regulates a Rac/JNK and a Rac/Nox pathway for DNA synthesis and Myc expression induced by growth factors. J. Cell Sci. 118 (2005) 3717-3726
53. Franco M., Furstoss O., Simon V., Benistant C., Hong W.J., and Roche S. The adaptor protein Tom1L1 is a negative regulator of Src mitogenic signaling induced by growth factors. Mol. Cell. Biol. 26 (2006) 1932-1947
54. Veracini L., Franco M., Boureux A., Simon V., Roche S., and Benistant C. Two distinct pools of Src family tyrosine kinases regulate PDGF-induced DNA synthesis and actin dorsal ruffles. J. Cell Sci. 119 (2006) 2921-2934
55. Boyer B., Roche S., Denoyelle M., and Thiery J.P. Src and Ras are involved in separate pathways in epithelial cell scattering. EMBO J. 16 (1997) 5904-5913
56. Benistant C., Chapuis H., Mottet N., Noletti J., Crapez E., Bali J.P., and Roche S. Deregulation of the cytoplasmic tyrosine kinase cSrc in the absence of a truncating mutation at codon 531 in human bladder carcinoma. Biochem. Biophys. Res. Commun. 273 (2000) 425-430
57. Benistant C., Bourgaux J.-F., Chapuis H., Mottet N., Roche S., and Bali J.-P. The COOH-terminal Src kinase Csk is a tumor antigen in human carcinoma. Cancer Res. 61 (2001) 1415-1420
58. Wary K.K., Mariotti A., Zurzolo C., and Giancotti F.G. A requirement for caveolin-1 and associated kinase Fyn in integrin signaling and anchorage-dependent cell growth. Cell 94 (1998) 625-634
59. Mastick C., Brady M., and Saltiel A. Insulin stimulates the tyrosine phosphorylation of caveolin. J. Cell Biol. 129 (1995) 1523-1531
60. Li S., Seitz R., and Lisanti M.P. Phosphorylation of caveolin by Src tyrosine kinases. J. Biol. Chem. 271 (1996) 3863-3868
61. Aoki T., Nomura R., and Fujimoto T. Tyrosine phosphorylation of caveolin-1 in the endothelium. Exp. Cell Res. 253 (1999) 629-636
62. Lu T.-L., Kuo F.-T., Lu T.-J., Hsu C.-Y., and Fu H.-W. Negative regulation of protease-activated receptor 1-induced Src kinase activity by the association of phosphocaveolin-1 with Csk. Cell. Signal. 18 (2006) 1977-1987
63. Echarri A., and Del Pozo A. Caveolae internalization regulates integrin-dependent signaling pathways. Cell Cycle 5 (2006) 2179-2182
64. Del Pozo M.A., Balasubramanian N., Alderson N.B., Kiosses W.B., Grande-Garcia A., Anderson R.G., and Schwartz M.A. Phospho-caveolin-1 mediates integrin-regulated membrane domain internalisation. Nat. Cell Biol. 7 (2005) 901-908
65. Del Pozo M.A., and Schwartz M.A. Rac, membrane heterogeneity, caveolin and regulation of growth by integrins. Trends Cell Biol. 17 (2007) 246-250
66. Hakomori S., and Handa K. Glycosphingolipid-dependent cross-talk between glycosynapses interfacing tumor cells with their host cells: essential basis to define tumor malignancy. FEBS Lett. 531 (2002) 88-92
67. Iwabuchi K., Yamamura S., Prinetti A., Handa K., and Hakomori S. GM3-enriched microdomain involved in cell adhesion and signal transduction through carbohydrate-carbohydrate interaction in mouse melanoma B16 cells. J. Biol. Chem. 273 (1998) 9130-9138
68. Prinetti A., Iwabuchi K., and Hakomori S. Glycosphingolipid-enriched signaling domain in mouse neuroblastoma Neuro2a cells. Mechanism of ganglioside-dependent neuritogenesis. J. Biol. Chem. 274 (1999) 20916-20924
69. Satoh M., Nejad F.M., Ohtani H., Ito A., Ohyama C., Saito S., Orikasa S., and Hakomori S. Association of renal cell carcinoma antigen, disialylgalactosylgloboside, with c-Src and Rho A in clustered domains at the surface membrane. Int. J. Oncol. 16 (2000) 529-536
70. Steelant W.F., Kawakami Y., Ito A., Handa K., Bruyneel E.A., Mareel M., and Hakomori S. Monosialyl-Gb5 organized with cSrc and FAK in GEM of human breast carcinoma MCF-7 cells defines their invasive properties. FEBS Lett. 531 (2002) 93-98
71. Hemler M.E. Integrin associated proteins. Curr. Opin. Cell Biol. 10 (1998) 578-585
72. Kawakami Y., Kawakami K., Steelant W.F.A., Ono M., Baek R.C., Handa K., Withers D.A., and Hakomori S. Tetraspanin CD9 is a "proteolipid," and its interaction with alpha 3 integrin in microdomain is promoted by GM3 ganglioside, leading to inhibition of laminin-5-dependent cell motility. J. Biol. Chem. 277 (2002) 34349-34358
73. Miura Y., Kainuma M., Jiang H., Velasco H., Vogt P.K., and Hakomori S. Reversion of the Jun-induced oncogenic phenotype by enhanced synthesis of sialosyllactosylceramide (GM3 ganglioside). Proc. Natl. Acad. Sci. U. S. A. 101 (2004) 16204-16209
74. Mitsuzuka K., Handa K., Satoh M., Arai Y., and Hakomori S. A specific microdomain ("glycosynapse 3") controls phenotypic conversion and reversion of bladder cancer cells through GM3-mediated interaction of alpha3beta1 integrin with CD9. J. Biol. Chem. 280 (2005) 35545-35553
75. Toledo M.S., Suzuki E., Handa K., and Hakomori S. Effect of ganglioside and tetraspanins in microdomains on interaction of integrins with fibroblast growth factor receptor. J. Biol. Chem. 280 (2005) 16227-16234
76. Todeschini A.R., Dos Santos J.N., Handa K., and Hakomori S.-I. Ganglioside GM2-tetraspanin CD82 complex inhibits Met and its cross-talk with integrins, providing a basis for control of cell motility through glycosynapse. J. Biol. Chem. 282 (2007) 8123-8133
77. Iwabuchi K., Zhang Y., Handa K., Withers D.A., Sinay P., and Hakomori S.-I. Reconstitution of membranes simulating "glycosignaling domain" and their susceptibility to Lyso-GM3. J. Biol. Chem. 275 (2000) 15174-15181
78. Ono M., Handa K., Withers D.A., and Hakomori S.-I. Glycosylation effect on membrane domain (GEM) involved in cell adhesion and motility: a preliminary note on functional [alpha]3, [alpha]5-CD82 glycosylation complex in ldlD 14 cells. Biochem. Biophys. Res. Commun. 279 (2000) 744-750
79. Kazui A., Ono M., Handa K., and Hakomori S.-I. Glycosylation affects translocation of integrin, Src, and caveolin into or out of GEM. Biochem. Biophys. Res. Commun. 273 (2000) 159-163
80. Zhang Y., Iwabuchi K., Nunomura S., and Hakomori S. Effect of synthetic sialyl 2→1 sphingosine and other glycosylsphingosines on the structure and function of the "glycosphingolipid signaling domain (GSD)" in mouse melanoma B16 cells. Biochemistry 39 (2000) 2459-2468
81. Palade G.E. An electron microscope study of the mitochondrial structure. J. Histochem. Cytochem. 1 (1953) 188-211
82. Yamada E. The fine structure of the gall bladder epithelium of the mouse. J. Biophys. Biochem. Cytol. 1 (1955) 445-458
83. Lisanti M.P., Scherer P.E., Tang Z., and Sargiacomo M. Caveolae, caveolin and caveolin-rich membrane domains: a signalling hypothesis. Trends Cell Biol. 4 (1994) 231-235
84. Okamoto T., Schlegel A., Scherer P.E., and Lisanti M.P. Caveolins, a family of scaffolding proteins for organizing "preassembled signaling complexes" at the plasma membrane. J. Biol. Chem. 273 (1998) 5419-5422
85. Fielding C.J. Caveolae and signaling. Curr. Opin. Lipidol. 12 (2001) 281-287
86. Chini B., and Parenti M. G-protein coupled receptors in lipid rafts and caveolae: how, when and why do they go there?. J. Mol. Endocrinol. 32 (2004) 325-338
87. Drab M., Verkade P., Elger M., Kasper M., Lohn M., Lauterbach B., Menne J., Lindschau C., Mende F., Luft F.C., Schedl A., Haller H., and Kurzchalia T.V. Loss of caveolae, vascular dysfunction, and pulmonary defects in caveolin-1 gene-disrupted mice. Science 293 (2001) 2449-2452
88. Galbiati F., Engelman J.A., Volonte D., Zhang X.L., Minetti C., Li M., Hou Jr. H., Kneitz B., Edelmann W., and Lisanti M.P. Caveolin-3 null mice show a loss of caveolae, changes in the microdomain distribution of the dystrophin-glycoprotein complex, and t-tubule abnormalities. J. Biol. Chem. 276 (2001) 21425-21433
89. Fra A.M., Williamson E., Simons K., and Parton R.G. De novo formation of caveolae in lymphocytes by expression of VIP21-caveolin. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 8655-8659
90. Sowa G., Pypaert M., and Sessa W.C. Distinction between signaling mechanisms in lipid rafts vs. caveolae. Proc. Natl. Acad. Sci. U. S. A. 98 (2001) 14072-14077
91. Westermann M., Leutbecher H., and Meyer H.W. Membrane structure of caveolae and isolated caveolin-rich vesicles. Histochem. Cell Biol. 111 (1999) 71-81
92. Kurzchalia T.V., Dupree P., Parton R.G., Kellner R., Virta H., Lehnert M., and Simons K. VIP21, a 21-kD membrane protein is an integral component of trans-Golgi-network-derived transport vesicles. J. Cell Biol. 118 (1992) 1003-1014
93. Li W.P., Liu P., Pilcher B.K., and Anderson R.G. Cell-specific targeting of caveolin-1 to caveolae, secretory vesicles, cytoplasm or mitochondria. J. Cell Sci. 114 (2001) 1397-1408
94. Fujimoto T. GPI-anchored proteins, glycosphingolipids, and sphingomyelin are sequestered to caveolae only after crosslinking. J. Histochem. Cytochem. 44 (1996) 929-941
95. Stan R.V. Structure and function of endothelial caveolae. Microsc. Res. Tech. 57 (2002) 350-364
96. Nabi I.R., and Le P.U. Caveolae/raft-dependent endocytosis. J. Cell Biol. 161 (2003) 673-677
97. Nichols B. Caveosomes and endocytosis of lipid rafts. J. Cell Sci. 116 (2003) 4707-4714
98. Parton R.G., and Richards A.A. Lipid rafts and caveolae as portals for endocytosis: new insights and common mechanisms. Traffic 4 (2003) 724-738
99. Kenworthy A. Peering inside lipid rafts and caveolae. Trends Biochem. Sci. 27 (2002) 435-438
100. Hooper N.M. Detergent-insoluble glycosphingolipid/cholesterol-rich membrane domains, lipid rafts and caveolae (review). Mol. Membr. Biol. 16 (1999) 145-156
101. Sargiacomo M., Sudol M., Tang Z., and Lisanti M.P. Signal transducing molecules and glycosyl-phosphatidylinositol-linked proteins form a caveolin-rich insoluble complex in MDCK cells. J. Cell Biol. 122 (1993) 789-807
102. Prinetti A., Chigorno V., Prioni S., Loberto N., Marano N., Tettamanti G., and Sonnino S. Changes in the lipid turnover, composition, and organization, as sphingolipid-enriched membrane domains, in rat cerebellar granule cells developing in vitro. J. Biol. Chem. 276 (2001) 21136-21145
103. Fra A.M., Williamson E., Simons K., and Parton R.G. Detergent-insoluble glycolipid microdomains in lymphocytes in the absence of caveolae. J. Biol. Chem. 269 (1994) 30745-30748
104. Kasahara K., Watanabe K., Takeuchi K., Kaneko H., Oohira A., Yamamoto T., and Sanai Y. Involvement of gangliosides in glycosylphosphatidylinositol-anchored neuronal cell adhesion molecule TAG-1 signaling in lipid rafts. J. Biol. Chem. 275 (2000) 34701-34709
105. Kasahara K., Watanabe Y., Yamamoto T., and Sanai Y. Association of Src family tyrosine kinase Lyn with ganglioside GD3 in rat brain. Possible regulation of Lyn by glycosphingolipid in caveolae-like domains. J. Biol. Chem. 272 (1997) 29947-29953
106. Prinetti A., Prioni S., Chigorno V., Karagogeos D., Tettamanti G., and Sonnino S. Immunoseparation of sphingolipid-enriched membrane domains enriched in Src family protein tyrosine kinases and in the neuronal adhesion molecule TAG-1 by anti-GD3 ganglioside monoclonal antibody. J. Neurochem. 78 (2001) 1162-1167
107. Quest A.F., Leyton L., and Parraga M. Caveolins, caveolae, and lipid rafts in cellular transport, signaling, and disease. Biochem. Cell. Biol. 82 (2004) 129-144
108. Prinetti A., Marano N., Prioni S., Chigorno V., Mauri L., Casellato R., Tettamanti G., and Sonnino S. Association of Src-family protein tyrosine kinases with sphingolipids in rat cerebellar granule cells differentiated in culture. Glycoconj. J. 17 (2000) 223-232
109. Scheiffele P., Verkade P., Fra A.M., Virta H., Simons K., and Ikonen E. Caveolin-1 and -2 in the exocytic pathway of MDCK cells. J. Cell Biol. 140 (1998) 795-806
110. Maggi R., Pimpinelli F., Molteni L., Milani M., Martini L., and Piva F. Immortalized luteinizing hormone-releasing hormone neurons show a different migratory activity in vitro. Endocrinology 141 (2000) 2105-2112
111. Prioni S., Loberto N., Prinetti A., Chigorno V., Guzzi F., Maggi R., Parenti M., and Sonnino S. Sphingolipid metabolism and caveolin expression in gonadotropin-releasing hormone-expressing GN11 and gonadotropin-releasing hormone-secreting GT1-7 neuronal cells. Neurochem. Res. 27 (2002) 831-840
112. Mayor S., Rothberg K., and Maxfield F. Sequestration of GPI-anchored proteins in caveolae triggered by cross-linking. Science 264 (1994) 1948-1951
113. Stan R.V., Roberts W.G., Predescu D., Ihida K., Saucan L., Ghitescu L., and Palade G.E. Immunoisolation and partial characterization of endothelial plasmalemmal vesicles (caveolae). Mol. Biol. Cell 8 (1997) 595-605
114. Waugh M.G., Lawson D., and Hsuan J.J. Epidermal growth factor receptor activation is localized within low-buoyant density, non-caveolar membrane domains. Biochem. J. 337 Pt 3 (1999) 591-597
115. Waugh M.G., Minogue S., Anderson J.S., dos Santos M., and Hsuan J.J. Signalling and non-caveolar rafts. Biochem. Soc. Trans. 29 (2001) 509-511
116. Ringerike T., Blystad F.D., Levy F.O., Madshus I.H., and Stang E. Cholesterol is important in control of EGF receptor kinase activity but EGF receptors are not concentrated in caveolae. J. Cell Sci. 115 (2002) 1331-1340
117. Roepstorff K., Thomsen P., Sandvig K., and van Deurs B. Sequestration of epidermal growth factor receptors in non-caveolar lipid rafts inhibits ligand binding. J. Biol. Chem. 277 (2002) 18954-18960
118. Fujimoto T., Hayashi M., Iwamoto M., and Ohno-Iwashita Y. Crosslinked plasmalemmal cholesterol is sequestered to caveolae: analysis with a new cytochemical probe. J. Histochem. Cytochem. 45 (1997) 1197-1205
119. Murata M., Peranen J., Schreiner R., Wieland F., Kurzchalia T.V., and Simons K. VIP21/Caveolin is a cholesterol-binding protein. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 10339-10343
120. Li S., Song K.S., and Lisanti M.P. Expression and characterization of recombinant caveolin. J. Biol. Chem. 271 (1996) 568-573
121. Thiele C., Hannah M.J., Fahrenholz F., and Huttner W.B. Cholesterol binds to synaptophysin and is required for biogenesis of synaptic vesicles. Nat. Cell Biol. 2 (2000) 42-49
122. Parton R.G. Ultrastructural localization of gangliosides; GM1 is concentrated in caveolae. J. Histochem. Cytochem. 42 (1994) 155-166
123. Schnitzer J.E., McIntosh D.P., Dvorak A.M., Liu J., and Oh P. Separation of caveolae from associated microdomains of GPI-anchored proteins. Science 269 (1995) 1435-1439
124. Liu P., and Anderson R.G. Compartmentalized production of ceramide at the cell surface. J. Biol. Chem. 270 (1995) 27179-27185
125. Chigorno V., Palestini P., Sciannamblo M., Dolo V., Pavan A., Tettamanti G., and Sonnino S. Evidence that ganglioside enriched domains are distinct from caveolae in MDCK II and human fibroblast cells in culture. Eur. J. Biochem. 267 (2000) 4187-4197
126. Fra A.M., Masserini M., Palestini P., Sonnino S., and Simons K. A photo-reactive derivative of ganglioside GM1 specifically cross-links VIP21-caveolin on the cell surface. FEBS Lett. 375 (1995) 11-14
127. Resh M.D. Fatty acylation of proteins: new insights into membrane targeting of myristoylated and palmitoylated proteins. Biochim. Biophys. Acta, Mol. Cell Res. 1451 (1999) 1-16
128. Robbins S., Quintrell N., and Bishop J. Myristoylation and differential palmitoylation of the HCK protein-tyrosine kinases govern their attachment to membranes and association with caveolae. Mol. Cell. Biol. 15 (1995) 3507-3515
129. Shenoy-Scaria A., Dietzen D., Kwong J., Link D., and Lublin D. Cysteine3 of Src family protein tyrosine kinase determines palmitoylation and localization in caveolae. J. Cell Biol. 126 (1994) 353-363
130. Wolven A., Okamura H., Rosenblatt Y., and Resh M. Palmitoylation of p59fyn is reversible and sufficient for plasma membrane association. Mol. Biol. Cell 8 (1997) 1159-1173
131. Janes P.W., Ley S.C., Magee A.I., and Kabouridis P.S. The role of lipid rafts in T cell antigen receptor (TCR) signalling. Semin. Immunol. 12 (2000) 23-34
132. Mukherjee A., Arnaud L., and Cooper J.A. Lipid-dependent recruitment of neuronal Src to lipid rafts in the brain. J. Biol. Chem. 278 (2003) 40806-40814
133. Melkonian K.A., Ostermeyer A.G., Chen J.Z., Roth M.G., and Brown D.A. Role of lipid modifications in targeting proteins to detergent-resistant membrane rafts. Many raft proteins are acylated, while few are prenylated. J. Biol. Chem. 274 (1999) 3910-3917
134. Lee H., Volonte' D., Galbiati F., Iyengar P., Lublin D.M., Bregman D.B., Wilson M.T., Campos-Gonzalez R., Bouzahzah B., Pestell R.G., Scherer P.E., and Lisanti M.P. Constitutive and growth factor-regulated phosphorylation of caveolin-1 occurs at the same site (Tyr-14) in vivo: identification of a c-Src/Cav-1/Grb7 signaling cassette. Mol. Endocrinol. 14 (2000) 1750-1775
135. Sharma D.K., Brown J.C., Choudhury A., Peterson T.E., Holicky E., Marks D.L., Simari R., Parton R.G., and Pagano R.E. Selective stimulation of caveolar endocytosis by glycosphingolipids and cholesterol. Mol. Biol. Cell 15 (2004) 3114-3122
136. Shajahan A.N., Timblin B.K., Sandoval R., Tiruppathi C., Malik A.B., and Minshall R.D. Role of Src-induced dynamin-2 phosphorylation in caveolae-mediated endocytosis in endothelial cells. J. Biol. Chem. 279 (2004) 20392-20400
137. Pelkmans L., and Zerial M. Kinase-regulated quantal assemblies and kiss-and-run recycling of caveolae. Nature 436 (2005) 128-133
138. Da Silva J.S., Hasegawa T., Miyagi T., Dotti C.G., and Abad-Rodriguez J. Asymmetric membrane ganglioside sialidase activity specifies axonal fate. Nat. Neurosci. 8 (2005) 606-615
139. Kakugawa Y., Wada T., Yamaguchi K., Yamanami H., Ouchi K., Sato I., and Miyagi T. Up-regulation of plasma membrane-associated ganglioside sialidase (Neu3) in human colon cancer and its involvement in apoptosis suppression. Proc. Natl. Acad. Sci. U. S. A. 99 (2002) 10718-10723
140. Ueno S., Saito S., Wada T., Yamaguchi K., Satoh M., Arai Y., and Miyagi T. Plasma membrane-associated sialidase is up-regulated in renal cell carcinoma and promotes interleukin-6-induced apoptosis suppression and cell motility. J. Biol. Chem. 281 (2006) 7756-7764
141. Kalka D., von Reitzenstein C., Kopitz J., and Cantz M. The plasma membrane ganglioside sialidase cofractionates with markers of lipid rafts. Biochem. Biophys. Res. Commun. 283 (2001) 989-993
142. Wang Y., Yamaguchi K., Wada T., Hata K., Zhao X., Fujimoto T., and Miyagi T. A close association of the ganglioside-specific sialidase Neu3 with caveolin in membrane microdomains. J. Biol. Chem. 277 (2002) 26252-26259
143. Papini N., Anastasia L., Tringali C., Croci G., Bresciani R., Yamaguchi K., Miyagi T., Preti A., Prinetti A., Prioni S., Sonnino S., Tettamanti G., Venerando B., and Monti E. The plasma membrane-associated sialidase MmNEU3 modifies the ganglioside pattern of adjacent cells supporting its involvement in cell-to-cell interactions. J. Biol. Chem. 279 (2004) 16989-16995
144. Cremesti A.E., Goni F.M., and Kolesnick R. Role of sphingomyelinase and ceramide in modulating rafts: do biophysical properties determine biologic outcome?. FEBS Lett. 531 (2002) 47-53
145. Yu C., Alterman M., and Dobrowsky R.T. Ceramide displaces cholesterol from lipid rafts and decreases the association of the cholesterol binding protein caveolin-1. J. Lipid Res. 46 (2005) 1678-1691
146. Veldman R.J., Maestre N., Aduib O.M., Medin J.A., Salvayre R., and Levade T. A neutral sphingomyelinase resides in sphingolipid-enriched microdomains and is inhibited by the caveolin-scaffolding domain: potential implications in tumour necrosis factor signalling. Biochem. J. 355 (2001) 859-868
147. Wang X.-Q., Sun P., and Paller A.S. Ganglioside induces caveolin-1 redistribution and interaction with the epidermal growth factor receptor. J. Biol. Chem. 277 (2002) 47028-47034
148. Hamamura K., Furukawa K., Hayashi T., Hattori T., Nakano J., Nakashima H., Okuda T., Mizutani H., Hattori H., Ueda M., Urano T., Lloyd K.O., and Furukawa K. Ganglioside GD3 promotes cell growth and invasion through p130Cas and paxillin in malignant melanoma cells. Proc. Natl. Acad. Sci. U. S. A. 102 (2005) 11041-11046
149. Nakashima H., Hamamura K., Houjou T., Taguchi R., Yamamoto N., Mitsudo K., Tohnai I., Ueda M., Urano T., Furukawa K., and Furukawa K. Overexpression of caveolin-1 in a human melanoma cell line results in dispersion of ganglioside GD3 from lipid rafts and alteration of leading edges, leading to attenuation of malignant properties. Cancer Sci. 98 (2007) 512-520